Objective
The objective of the proposal is to establish stable cell lines that reliably reflect human hepatic properties by the development of models derived from human embryonic stem cells (hESC). The aim is to deliver reliable in vitro models that can be used by the pharmaceutical industry to replace experimental animals in investigations on human drug metabolism, uptake and efflux properties of compounds in the drug discovery and development processes. In the pharmaceutical industry reliable in vitro cell models would replace current techniques and animal experimentation in the selection and optimisation of lead compounds and in documentation of a selected drug candidate before it enters clinical phases.
The means to accomplish the objective are in addition to hESC derived hepatocytes, (1) 3D-hepatic cell methods, (2) micro-cultivation monitoring for in vitro screening, (3) genomic and metabolomic characterization, and (4) a multi-micro-bioreactors for high-throughput screening of drug candidates. Comparative studies with established in vitro models will be carried out to validate the new models/methods.
The outcome of the project is new pre-validation models which will reduce the use of animal experimentation for prediction of human drug metabolism and disposition by 60-80%. In addition, the models will also increase safety and quality of compounds chosen as candidates in the different stages of the drug discovery and development process. Furthermore, it will strengthen the possibility for SMEs to market new potential products for assays and in vitro screening.
The clinical expertise in the project includes two renowned European university hospitals, one SME founded by another European university hospital, and a larger pharmaceutical company. The coordinator and several partners have a background from pharmaceutical industry which is paired with partners very experienced in bioengineering.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences medical biotechnology cells technologies stem cells
- medical and health sciences basic medicine pharmacology and pharmacy pharmacokinetics
- medical and health sciences basic medicine pharmacology and pharmacy adverse drug reactions
- medical and health sciences basic medicine toxicology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2004-LIFESCIHEALTH-5
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
LINKÖPING
Sweden
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.